ABCL635 Meets Phase 2 Menopause Endpoints

Company: AbCellera · Event Type: Clinical/Regulatory Signal · Product/Asset: ABCL635 · Subject: Menopausal Vasomotor Symptoms · Event Date: August 10, 2026 Summary AbCellera reported that a single 600 mg subcutaneous dose of ABCL635, an antibody antagonist of the neurokinin-3 receptor, met both Phase 2 primary…